MaxCyte, Inc. Cost of Revenue
MaxCyte, Inc. (MXCT) reported Cost of Revenue of $1.68 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-13
- MaxCyte, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $1.68M, a 10.27% increase year-over-year.
- MaxCyte, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $1.57M, a 4.81% increase year-over-year.
- MaxCyte, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $1.61M, a 29.42% decline year-over-year.
- MaxCyte, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $1.60M, a 17.22% decline year-over-year.
- MaxCyte, Inc. cost of goods and services sold for fiscal 2025 was $6.22M, a 12.37% decline from fiscal 2024.
- MaxCyte, Inc. cost of goods and services sold for fiscal 2024 was $7.10M, a 49.73% increase from fiscal 2023.
- MaxCyte, Inc. cost of goods and services sold for fiscal 2023 was $4.74M, a 6.98% decline from fiscal 2022.
- MaxCyte, Inc. cost of goods and services sold for fiscal 2022 was $5.10M, a 39.77% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.68M 10-Q · filed 2026-08-13 | $3.24M 10-Q · filed 2026-08-13 | $4.85M derived: sum of 3 quarters · filed 2026-08-13 | $6.45M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $1.57M 10-Q · filed 2026-05-13 | $3.18M derived: sum of 2 quarters · filed 2026-05-13 | $4.78M derived: sum of 3 quarters · filed 2026-05-13 | $6.29M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $3.21M derived: sum of 2 quarters · filed 2026-03-25 | $4.72M derived: sum of 3 quarters · filed 2026-08-13 | $6.22M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $1.60M 10-Q · filed 2025-11-13 | $3.12M derived: sum of 2 quarters · filed 2026-08-13 | $4.61M 10-Q · filed 2025-11-13 | $6.89M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.52M 10-Q · filed 2026-08-13 | $3.02M 10-Q · filed 2026-08-13 | $5.30M derived: sum of 3 quarters · filed 2026-08-13 | $7.22M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $1.50M 10-Q · filed 2026-05-13 | $3.78M derived: sum of 2 quarters · filed 2026-05-13 | $5.71M derived: sum of 3 quarters · filed 2026-05-13 | $7.19M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.21M derived: sum of 2 quarters · filed 2026-03-25 | $5.70M derived: sum of 3 quarters · filed 2026-03-25 | $7.10M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $1.93M 10-Q · filed 2025-11-13 | $3.42M derived: sum of 2 quarters · filed 2025-11-13 | $4.82M 10-Q · filed 2025-11-13 | $6.39M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $1.49M 10-Q · filed 2025-08-06 | $2.89M 10-Q · filed 2025-08-06 | $4.46M derived: sum of 3 quarters · filed 2025-08-06 | $5.26M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $1.40M 10-Q · filed 2025-05-08 | $2.98M derived: sum of 2 quarters · filed 2025-05-08 | $3.77M derived: sum of 3 quarters · filed 2025-05-08 | $5.14M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $2.37M derived: sum of 2 quarters · filed 2025-03-11 | $3.74M derived: sum of 3 quarters · filed 2025-03-11 | $4.74M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $793.00K 10-Q · filed 2024-11-06 | $793.40K 10-Q · filed 2023-11-08 | $2.17M derived: sum of 2 quarters · filed 2024-11-06 | $3.17M 10-Q · filed 2024-11-06 | $3.17M 10-Q · filed 2023-11-08 | $4.72M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $1.38M 10-Q · filed 2024-08-06 | $1.38M 10-Q · filed 2023-08-09 | $2.38M 10-Q · filed 2024-08-06 | $2.38M 10-Q · filed 2023-08-09 | $3.92M derived: sum of 3 quarters · filed 2024-08-06 | $5.29M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $1.00M 10-Q · filed 2024-05-07 | $999.80K 10-Q · filed 2023-05-10 | $2.55M derived: sum of 2 quarters · filed 2024-05-07 | $3.92M derived: sum of 3 quarters · filed 2024-05-07 | $5.04M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $2.92M derived: sum of 2 quarters · filed 2024-03-12 | $4.04M derived: sum of 3 quarters · filed 2024-03-12 | $5.10M 10-K · filed 2024-03-12 | $5.10M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $1.37M 10-Q · filed 2023-11-08 | $2.49M derived: sum of 2 quarters · filed 2023-11-08 | $3.55M 10-Q · filed 2023-11-08 | $4.78M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $1.12M 10-Q · filed 2023-08-09 | $2.18M 10-Q · filed 2023-08-09 | $3.41M derived: sum of 3 quarters · filed 2023-08-09 | $4.35M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $1.06M 10-Q · filed 2023-05-10 | $2.29M derived: sum of 2 quarters · filed 2023-05-10 | $3.23M derived: sum of 3 quarters · filed 2023-05-10 | $4.02M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $2.17M derived: sum of 2 quarters · filed 2023-03-15 | $2.95M derived: sum of 3 quarters · filed 2023-03-15 | $3.65M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $943.80K 10-Q · filed 2022-11-09 | $1.73M derived: sum of 2 quarters · filed 2022-11-09 | $2.42M 10-Q · filed 2022-11-09 | |||||
| 2021-06-30 | $784.50K 10-Q · filed 2022-08-10 | $1.48M 10-Q · filed 2022-08-10 | ||||||
| 2021-03-31 | $693.10K 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | $2.77M 10-K · filed 2022-03-22 | |||||||
| 2019-12-31 | $2.50M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |